From Banks to FinTech: The Evolution of Small Business Lending — The Consumer Finance Podcast
From Banks to FinTech: The Evolution of Small Business Lending — Payments Pros – The Payments Law Podcast
State AG Pulse | A FAIR Go For NY Consumers
NYS Gov. Hochul’s 2025 State of the State – Legislative Recap
Florida’s Equine Landscape
Unveiling Gender-Affirming Care: Why It Matters and What’s at Stake – Diagnosing Health Care
AI Law in the Commonwealth of Virginia - Recent Developments
Proof in Trial: Moore v. Harper
Video: Things to Remember in Q1 when Preparing 2024 Federal Lobbying Disclosure Act (LDA) Reports
Podcast: Discussing Florida’s 2024 Legislative Session
33rd Annual Legislative Seminar - Senator Shelley Moore Capito, R-W.Va.
33rd Annual Legislative Seminar - Congressman Raja Krishnamoorthi, D-Ill
Orrick Public Policy Podcast #23 – A Conversation with Virginia Delegate Schuyler VanValkenburg
Overview of 87th Texas Legislature
Labor & Employment Law: Vermont and Federal Legislative Update
Lowndes Client Corner Podcast Episode 5 - Winter Park Distilling Company Brews One-Of-A-Kind Facility in Winter Park
California legislators recently introduced AB 1460, which would prohibit prescription drug manufacturers from engaging in discriminatory practices aimed at providers participating in the 340B drug pricing program (covered...more
Amidst the usual suits and blazers, white dresses and tuxedos have been appearing with increasing frequency around the Georgia State Capitol this spring. Apparently word is out amongst the city’s photographers that the...more
Proposition 34 requires certain California healthcare providers to spend at least 98% of their net drug sale revenue on direct patient care. The measure targets certain providers who benefit from a federal drug discount...more
States remain at the forefront of legislative efforts on a range of issues relating to drug pricing, such as increasing price transparency, capping out-of-pocket costs for insulin, and limiting certain PBM practices. These...more
In 2019, U.S. Department of Justice (DOJ) enforcement activity targeting drug and device manufacturers jumped sharply over the prior year, reflecting an increased focus on fraud and abuse in the life sciences sector. More...more